ANONYMOUS: "A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis - ClinicalTrials.gov", 8 May 2014 (2014-05-08), XP055460104, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/NCT01452685?term=TAK-385&draw=3&rank=12> [retrieved on 20180316] (B1)

Wu, D. et. al., Arch. Gynecol. Obstet. 2014, 513-523; (B2)

ANONYMOUS: "Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids - Full Text View - ClinicalTrials.gov", 21 January 2013 (2013-01-21), XP055460100, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/NCT01452659?term=TAK-385&rank=9> [retrieved on 20180316] (B1)

ANONYMOUS: "NCT02655224 on 2016_09_29: ClinicalTrials.gov Archive", 29 September 2016 (2016-09-29), XP055460097, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02655224/2016_09_29> [retrieved on 20180316] (B1)

ANONYMOUS: "NCT02655237 on 2016_09_14: ClinicalTrials.gov Archive", 14 September 2016 (2016-09-14), XP055460098, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02655237/2016_09_14> [retrieved on 20180316] (B1)

ANONYMOUS: "Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer", 6 June 2016 (2016-06-06), XP055459497, Retrieved from the Internet <URL:http://investors.myovant.com/tools/viewpdf.aspx?page={7F19DBB5-53F9-43CE-8BF9-CCE79BD044BD}> [retrieved on 20180314] (B1)

DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1998 (1998-01-01), HORNSTEIN M D ET AL: "Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.", XP002779261, Database accession no. NLM9464714 (B1)

HORNSTEIN M D ET AL: "Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.", OBSTETRICS AND GYNECOLOGY JAN 1998, vol. 91, no. 1, January 1998 (1998-01-01), pages 16 - 24, XP029904758, ISSN: 0029-7844, DOI: 10.1016/S0029-7844(97)00600-5 (B1)

KAZUHIRO MIWA ET AL: "Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3- d ]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 14, 28 July 2011 (2011-07-28), pages 4998 - 5012, XP055012890, ISSN: 0022-2623, DOI: 10.1021/jm200216q (B1)

M/S. REPORTSTACK: "Endometriosis - Opportunity Analysis and Forecasts to 2017", 4 February 2014 (2014-02-04), XP055460148, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/endometriosis---opportunity-analysis-and-forecasts-to-2017-243490131.html> [retrieved on 20180316] (B1)

NAKATA DAISUKE ET AL: "Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 723, 11 December 2013 (2013-12-11), pages 167 - 174, XP028607987, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2013.12.001 (B1)

OBSTETRICS AND GYNECOLOGY JAN 1998, vol. 91, no. 1, January 1998 (1998-01-01), pages 16 - 24, ISSN: 0029-7844 (B1)

WO-A1-2014/143669 (B1)

A. Al-Hendy et al., N. Engl. J. Med., 2021, 284(7), 630-642 (B2)

ANONYMOUS: "Myovant sciences Announces Late-Breaking oral Presentation of phase 3 Liberty 1&2 Study Results", MYOVANT SCIENCES, 10 October 2019 (2019-10-10), XP093012501, [retrieved on 20230110] (B2)

ANONYMOUS: "Roivant Sciences and Takeda Launch Myovant Sciences", TAKEDA PRESS RELEASE, 7 June 2016 (2016-06-07), XP093012511, [retrieved on 20230110] (B2)

Attar, R. et al., Women’s Health 2015, 11(5), 653-664; (B2)

C. Becker et al., Session 62, Abstracts of the 38th Hybrid Annual Meeting of the ESHRE, 3 6 July 2022, page i1 10 (B2)

Chwalisz, K. et al., “Fibroids”, First Edition, edited by James H. Segars, John Wiley & Sons, Ltd., 2013, Chapter 6 entitled “Medical Management of Women with Symptomatic Uterine Fibroids” (B2)

ClinicalTrials.gov archive, History of Changes for Study NCT02655224, last update submitted September 13, 2016 and posted on 15 September 2016 (B2)

ClinicalTrials.gov archive, History of Changes for Study NCT02655237, last update submitted September 13, 2016 and posted on 15 September 2016 (B2)

DONG-YUN LEE, HYANG GI PARK, BYUNG-KOO YOON, DOOSEOK CHOI: "Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis", OBSTETRICS & GYNECOLOGY SCIENCE, vol. 59, no. 1, 1 January 2016 (2016-01-01), pages 32, XP055304542, ISSN: 2287-8572, DOI: 10.5468/ogs.2016.59.1.32 (B2)

FRANCES BATZER R.: "GnRH agonist and antagonist: options for endometriosis pain treatment", THOMAS JEFFERSON UNIVERSITY, 1 November 2006 (2006-11-01), XP093012513, [retrieved on 20230110] (B2)

I. Duijkers et al., P-287, Abstracts of the 36th Annual Meeting of the ESHRE, 5 to 8 July 2020, page i268-i269 (B2)

L. C. Giudice et al., placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-2022; 399: 2267 79, published 25 August 2022 (B2)

McLaren, J.S. et al., Menopause Int. 2012, 18, 68-72; (B2)

Myovant Sciences + Pfizer publication in The Lancet of Phase 3 Spirit 1 and Spirit 2 studies of oncedaily relugolix combination therapy in women with endometriosis-, published 17 June 2022 (B2)

S. As-Sanie et al., O-1, ASRM 2022 Genes, Gametes, and Genetics, October 22-26 2022, Scientific Abstracts to be presented at the 78th Scientific Congress of the American Society for Reproductive Medicine, October 22-26, 2022, Anaheim, California, page e1 (B2)

ANONYMOUS: "Efficacy and Safety of TAK-385 in the Treatment of Endometriosis - ClinicalTrials.gov", 25 February 2014 (2014-02-25), XP055460103, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/NCT01458301?term=TAK-385&draw=2&rank=11> [retrieved on 20180316] (B1)